García RJC, Izu BRM, Amutio DE

Language: Spanish
References: 47
Page: 69-79
PDF size: 3974.00 Kb.

ABSTRACT

There is currently no curative treatment of cutaneous lymphomas in advanced stages. Historically these patients have been treated with chemotherapy regimens used in systemic lymphomas usually very toxic and with limited benefits. With the growing knowledge about the pathogenesis of cutaneous lymphomas it has been able to identify therapeutic targets and to develop new molecules that currently are being tested with promising results. This is the case of histone deacetylase inhibitors (IHDAC) and the new monoclonal antibodies, among others. In the same way it has been found that useful drugs in other tumors, such as gemcitabine, bortezomib and liposomal doxorubicin are also active in the LCP-T, at least in preliminary studies. In the last years, new drugs and therapeutic strategies are being added to our arsenal with the purpose of changing the natural history of this disease. In this article we review the therapeutic advances in this field.

REFERENCES

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. CJLM. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85

2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC): Lyon 2008.

3. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-31.

4. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a populationbased study of 3884 cases. Blood. 2009; 113: 5064-73.

5. Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008; 8 (S5): S187-92.

6. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous Tcell lymphoma. Curr Opin Oncol 2009; 21: 131-7.

7. Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson Get al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003; 101: 4267-72.

8. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009; 50: 1969-76.

9. O’Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand Jet al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111: 1816-9.

10. Ure UB, Ar MC, Salihoglu A, Guner SI, Baran A, Oguz O, Ferhanoglu B. Alemtuzumab in Sézary syndrome: efficient but not innocent. Eur J Dermatol 2007; 17: 525-9.

11. Osterborg A, Foà R, Bezares RF, Dearden C, Dyer MJ, Geisler C et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23: 1980-8.

12. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004; 104: 655-8.

13. Fisher DC, Tawa M, Walsh M, Clark RA, Kupper TS. Low-dose alemtuzumab is uniquely effective in refractory leukemic cutaneous T cell lymphoma (L-CTCL). Abstrat 3748. In: 51TH Annual Meeting of American Society of Hematology, 5–8 December 2009; New Orleans, Louisiana, USA.

14. Rider DA, Havenith CEG, de Ridder R, Schuurman J, Favre C, Cooper JC et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of Tcell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007; 67: 9945-53.

15. Ruuls SR, van Bueren JJL, van de Winkel JGJ, Parren PWH. Novel human antibody therapeutics: The age of the Umabs. Biotechnol J 2008; 3: 1157-71.

16. Kim YH, Duvic M, Obitz E, Gniadecki, Iversen L, Osterborg A et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-62.

17. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-68.

18. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Current Oncol 2008; 15: 237-43.

19. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009; 2: 31.

20. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.

21. Siegel D, Munster PN, Rubin E, IwamotoM, van Belle S, Hussein M et al. The combined safety and tolerability profile of vorinostatbased therapy for solid or hematologic malignancies. Abstrat 1710. In: 51TH Annual Meeting of American Society of Hematology, 5–8 December 2009; New Orleans, Louisiana, USA.

22. Duvic M, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S et al. The systemic effects of vorinostat in patients with cutaneous T-cell lymphoma: post-hoc analyses in patients with high blood tumor burden. Abstrat 1709. In: 51TH Annual Meeting of American Society of Hematology, 5–8 December 2009; New Orleans, Louisiana, USA.

23. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865-8.

24. Kim Y, Whittaker S, Demierre MF, Rook AH, Lerner A, Duvic M et al. Clinically Significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study. Abstract #263. In: 50TH Annual Meeting of American Society of Hematology, 6–9 December 2008; San Francisco, California, USA.

25. Kim YH, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M et al. Clinically significant responses achieved with romidepsin in 37 patients with cutaneous T-cell lymphoma with blood involvement. Abstrat 2683. En: 51TH Annual Meeting of American Society of Hematology, 5-8 December 2009; New Orleans, Louisiana, USA.

26. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.

27. Demierre M, Whittaker S, Kim Y, Kim E, Piekarz R, Prince M et al. Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma. Abstrat 8546. En: 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27: 15s.

28. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2: 22.

29. Duvic M, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL et al. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory cutaneous T-cell lymphoma (CTCL). Abstrat 8555. En: 2008 ASCO Annual Meeting. J Clin Oncol 2008; 26.

30. Stevens SR, Ke MS, Parry EJ, Mark J, Cooper KD. Quantifying skin disease burden in mycosis fungoides–type cutaneous T-cell lymphomas. The Severity-Weighted Assessment Tool (SWAT). Arch Dermatol 2002; 138: 42-8.

31. Pohlman B, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Abstrat 920. En: 51th Annual Meeting of American Society of Hematology, 5-8 December 2009; New Orleans, Louisiana, USA.

32. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. Abstrat 8552. En: 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27.

33. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients. Cancer 2005; 104: 2437-41.

34. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51-8.

35. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, Paul C, Chaoui D, Sigal-Grinberg M et al. Gemcitabine treatment in cutaneous T-cell lymphoma: multicentre study of 23 cases. Br J Dermatol 2009; 161: 660-3.

36. Horwitz SM, Duvic M, Kim Y, Zain JM, Lechowicz MJ, Myskowski P et al. Pralatrexate is active in cutaneous T-cell lymphoma: results of a multi-center dose-finding trial. Abstract 919. En: 51th Annual Meeting of American Society of Hematology, 5–8 December 2009; New Orleans, Louisiana, USA.

37. O’Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D et al. Phase III- II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27: 4357-64.

38. Quereux G, Marques S, Nguyen JM, Bedane C, D’incan M, Dereure OP et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary Syndrome. Arch Dermatol 2008; 144: 727-33.

39. Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used thera - pies. Eur J Haematol 2009; 82: 184-93.

40. Abruzzese E, Postorino M, Faraggiana T, Renzi D, Rizzo M, QuaresimaM et al. Pegylated liposomal doxorubicin, bleomycin, vinblastine and dacarbazine (CBVD) in the treatment of advanced primary cutaneous lymphomas. Abstrat 3717. En: 51th Annual Meeting of American Society of Hematology, 5-8 December 2009; New Orleans, Louisiana, USA.

41. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-12.

42. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous Tcell lymphoma. J Clin Oncol 2007; 25: 4293-7.

43. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G et al. Down-regulating constitutive activation of the NF- B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107: 2354-63.

44. Querfeld C, Kuzel TM, Guitar J, Rosen ST. Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. Hematology Meetings Reports 2009; 3: 103-5.

45. Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 2009; 82: 440-9.

46. Dummer R, Hymes K, Sterry W, Steinhoff M, Assaf C, Kerl H et al. Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. Abstrat 8572. En: 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27.

47. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70: 273-86.